Leveraging the Capabilities of the FDA's Sentinel System To Improve Kidney Care.
暂无分享,去创建一个
Richard Platt | David Martin | Jeffrey S Brown | Sruthi Adimadhyam | Erin F Barreto | Noelle M Cocoros | Sengwee Toh | Judith C Maro | Jacqueline Corrigan-Curay | Gerald J Dal Pan | Robert Ball | Michael Nguyen | Xiaojuan Li | R. Platt | G. D. Dal Pan | Jeffrey S. Brown | R. Ball | E. Barreto | N. Cocoros | S. Toh | M. Nguyen | J. Maro | David Martin | S. Adimadhyam | Xiaojuan Li | Jacqueline Corrigan‐Curay
[1] Mia Gallagher,et al. Validity of Privacy-Protecting Analytical Methods That Use Only Aggregate-Level Information to Conduct Multivariable-Adjusted Analysis in Distributed Data Networks , 2018, American journal of epidemiology.
[2] Jason Roy,et al. Missing laboratory results data in electronic health databases: implications for monitoring diabetes risk. , 2017, Journal of comparative effectiveness research.
[3] Vlado Perkovic,et al. Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future? , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[4] W Katherine Yih,et al. Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010. , 2012, American journal of epidemiology.
[5] S Toh,et al. Successful Comparison of US Food and Drug Administration Sentinel Analysis Tools to Traditional Approaches in Quantifying a Known Drug‐Adverse Event Association , 2016, Clinical pharmacology and therapeutics.
[6] Richard Platt,et al. The FDA Sentinel Initiative - An Evolving National Resource. , 2018, The New England journal of medicine.
[7] Alexandra-Chloé Villani,et al. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. , 2019, Clinical journal of the American Society of Nephrology : CJASN.
[8] Thomas P. Gross,et al. The US Food and Drug Administration's Sentinel Initiative: Expanding the horizons of medical product safety , 2012, Pharmacoepidemiology and drug safety.
[9] Lesley H. Curtis,et al. Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data , 2019, Supportive Care in Cancer.
[10] Mark L Unruh,et al. Primary care physicians’ familiarity, beliefs, and perceived barriers to practice guidelines in non-diabetic CKD: a survey study , 2014, BMC Nephrology.
[11] J. Zhang,et al. Use of Mepolizumab Among Individuals with Asthma in the U.S. , 2020 .
[12] Andrew Davenport,et al. Phenotype Standardization for Drug Induced Kidney Disease , 2015, Kidney international.
[13] Richard Platt,et al. Four health data networks illustrate the potential for a shared national multipurpose big-data network. , 2014, Health affairs.
[14] J. C. Maro,et al. SAT0140 Risk of venous thromboembolism in rheumatoid arthritis patients treated with biologic and non-biologic dmards , 2018, Saturday, 16 JUNE 2018.
[15] G. Niklas Norén,et al. Temporal pattern discovery in longitudinal electronic patient records , 2010, Data Mining and Knowledge Discovery.
[16] Andrew Bate,et al. Do FDA label changes work? Assessment of the 2010 class label change for proton pump inhibitors using the Sentinel System's analytic tools , 2018, Pharmacoepidemiology and drug safety.
[17] W Katherine Yih,et al. Intussusception risk after rotavirus vaccination in U.S. infants. , 2014, The New England journal of medicine.
[18] Vinit Nair,et al. FDA-Catalyst—Using FDA’s Sentinel Initiative for large-scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trial , 2018, Clinical trials.
[19] Sebastian Schneeweiss,et al. Data Mining for Adverse Drug Events With a Propensity Score-matched Tree-based Scan Statistic , 2018, Epidemiology.
[20] Robert L Davis,et al. Drug safety data mining with a tree‐based scan statistic , 2013, Pharmacoepidemiology and drug safety.
[21] R. Platt,et al. Distributed Health Data Networks: A Practical and Preferred Approach to Multi-Institutional Evaluations of Comparative Effectiveness, Safety, and Quality of Care , 2010, Medical care.
[22] R. Platt,et al. Developing the Sentinel System--a national resource for evidence development. , 2011, The New England journal of medicine.
[23] Vinay Prasad,et al. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs , 2019, JAMA network open.
[24] Vinit Nair,et al. Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AFib). , 2020, American heart journal.
[25] M. Perazella,et al. Pharmacology behind Common Drug Nephrotoxicities. , 2018, Clinical journal of the American Society of Nephrology : CJASN.
[26] W. Cheungpasitporn,et al. Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis , 2015, PloS one.
[27] Bruce H Fireman,et al. Comparison of privacy‐protecting analytic and data‐sharing methods: A simulation study , 2018, Pharmacoepidemiology and drug safety.
[28] W Katherine Yih,et al. Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: A self-controlled risk interval and cohort study with null results , 2019, PLoS medicine.
[29] Christian Hampp,et al. Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis , 2019, Diabetes Care.
[30] Michael Nguyen,et al. The Food and Drug Administration's Post‐Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise , 2012, Pharmacoepidemiology and drug safety.
[31] John M Lachin,et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.
[32] Richard Platt,et al. Reproducing Protocol‐Based Studies Using Parameterizable Tools—Comparison of Analytic Approaches Used by Two Medical Product Surveillance Networks , 2020, Clinical pharmacology and therapeutics.
[33] Shayan Shirazian,et al. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. , 2020, Journal of the American Society of Nephrology : JASN.
[34] Kenneth G Saag,et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout , 2018, The New England journal of medicine.
[35] Richard Platt,et al. Incidence of statin use in older adults with and without cardiovascular disease and diabetes mellitus, January 2008- March 2018 , 2019, PloS one.
[36] Richard Platt,et al. Design of a National Distributed Health Data Network , 2009, Annals of Internal Medicine.
[37] Sascha Dublin,et al. Studying Medication Safety in Pregnancy: A Call for New Approaches, Resources, and Collaborations , 2020, Pediatrics.
[38] Adrian F Hernandez,et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. , 2012, Archives of internal medicine.
[39] Sengwee Toh,et al. Use of tumor necrosis factor‐alpha inhibitors during pregnancy among women who delivered live born infants , 2018, Pharmacoepidemiology and drug safety.
[40] Kristian B Filion,et al. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases , 2014, BMJ : British Medical Journal.
[41] Kamlesh Khunti,et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. , 2020, The lancet. Diabetes & endocrinology.
[42] Yea-Huei Kao Yang,et al. Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies , 2017, European Journal of Epidemiology.
[43] Kamlesh Khunti,et al. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis. , 2018, Primary care diabetes.